Skip to content
DataLookout
Menu

NCT07908004

A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Timeframe: Up to 81 days

Secondary (2)

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)

Arms and interventions

BI 3821001 treatment groupExperimental
Placebo groupPlacebo comparator

Drugs: BI 3821001, Placebo

Sites

1 site in 1 country

  • CRS Clinical Research Services Berlin GmbHBerlin, Germany